Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years

ClinicalTrials.gov ID: NCT01928472

Public ClinicalTrials.gov record NCT01928472. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase I Multi-center, Observer-Blind, Randomized Dose-Ranging Study of Adjuvanted and Non-Adjuvanted Cell Culture-Derived, Inactivated A/H7N9 Monovalent Subunit Influenza Virus Vaccine (H7N9c) in Adults 18 to <65 Years

Study identification

NCT ID
NCT01928472
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Novartis Vaccines
Industry
Enrollment
402 participants

Conditions and interventions

Conditions

Interventions

  • H7N9c low dose with adjuvant Biological
  • H7N9c medium dose with adjuvant Biological
  • H7N9c high dose with adjuvant Biological
  • H7N9c high dose without adjuvant Biological

Biological

Eligibility (public fields only)

Age range
18 Years to 64 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2013
Primary completion
Aug 31, 2014
Completion
Aug 31, 2014
Last update posted
Jun 10, 2019

2013 – 2014

United States locations

U.S. sites
6
U.S. states
5
U.S. cities
5
Facility City State ZIP Site status
Site 04: Accelovance San Diego California 92108
Site 01: Accelovance Melbourne Florida 32935
Site 02: Accelovance Peoria Illinois 61602
Site 03: Accelovance Rockville Maryland 20850
Site 05: Janet Lewis Salt Lake City Utah 84109
Site 06: Janet Lewis Salt Lake City Utah 84121

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01928472, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 10, 2019 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01928472 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →